Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Esperion Therapeutics, Inc. - Common Stock (NQ:ESPR)

2.500 -0.440 (-14.97%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,635,416
Open 2.760
Bid (Size) 2.530 (1,300)
Ask (Size) 2.560 (100)
Prev. Close 2.940
Today's Range 2.424 - 2.780
52wk Range 0.6925 - 3.940
Shares Outstanding 28,277,493
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
DoorDash Posts Downbeat Q3 Earnings, Joins elf Beauty, Duolingo, HubSpot And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
 
Via Benzinga
Esperion Therapeutics Inc (NASDAQ:ESPR) Reports Mixed Q3 2025 Results with Revenue Beat and Wider Loss
Esperion's Q3 2025 shows strong revenue growth beating estimates, but a deeper loss led to a sharp stock sell-off. The company secured key patents and targets profitability in 2026. 
Via Chartmill
Topics Intellectual Property

Performance

YTD
+13.6%
+13.6%
1 Month
-19.9%
-19.9%
3 Month
+30.2%
+30.2%
6 Month
+187.1%
+187.1%
1 Year
+17.9%
+17.9%

More News

Read More
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Snap Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Earnings Scheduled For November 6, 2025
Via Benzinga
Why Is Esperion Therapeutics Stock Sinking Premarket Today?
Via Stocktwits
Esperion Shares Rally After Patent Litigation Settlement For Cholesterol Drugs
Via Stocktwits
Topics Intellectual Property
Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in Jefferies Global Healthcare Conference - London
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2:00 p.m. ET.
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Report Third Quarter 2025 Financial Results on November 6
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Nominates ESP-2001 as Preclinical Development Candidate for Treatment of Primary Sclerosing Cholangitis
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Dow Jumps Over 100 Points; US Crude Oil Inventories Increase
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
These stocks that are showing activity before the opening bell on Wednesday.
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Penguin Solutions Posts Q4 Earnings, Joins Esperion Therapeutics, Joby Aviation And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Why Confluent Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Esperion Announces Pricing of Public Offering of Common Stock
From Esperion Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Curious about the stocks that are showing activity after the closing bell on Tuesday?
Via Chartmill
Esperion Announces Proposed Public Offering of Common Stock
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040
From Esperion Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Esperion Therapeutics, Inc. - Common Stock publicly traded?
Yes, Esperion Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Esperion Therapeutics, Inc. - Common Stock trade on?
Esperion Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Esperion Therapeutics, Inc. - Common Stock?
The ticker symbol for Esperion Therapeutics, Inc. - Common Stock is ESPR on the Nasdaq Stock Market
What is the current price of Esperion Therapeutics, Inc. - Common Stock?
The current price of Esperion Therapeutics, Inc. - Common Stock is 2.500
When was Esperion Therapeutics, Inc. - Common Stock last traded?
The last trade of Esperion Therapeutics, Inc. - Common Stock was at 11/06/25 04:00 PM ET
What is the market capitalization of Esperion Therapeutics, Inc. - Common Stock?
The market capitalization of Esperion Therapeutics, Inc. - Common Stock is 70.69M
How many shares of Esperion Therapeutics, Inc. - Common Stock are outstanding?
Esperion Therapeutics, Inc. - Common Stock has 71M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.